While there are no FDA-approved biomarkers predictive of iAEs, there is a growing body of preclinic and retrospective research trying to address this important question. Eosinophilia may be a potentially useful biomarker and this is supported by several retrospective studies 1,2. It is intrigui...

Currently, there are no validated biomarkers for predicting which patients treated with ICPi’s will develop irAEs, although this is an active area of investigation with emerging signals that appear to correlate with certain irAEs.

There are no known biomarkers at this time.